Improving intraperitoneal adenovirus virotherapy for ovarian cancer
<p>The use of intraperitoneal (i.p.) adenovirus virotherapy of ovarian cancer is currently limited by insufficient efficacy and high toxicity. Both factors are associated with adenovirus serotype 5 (Ad5) in this setting and may be serotype-specific. Low levels of uptake receptors (CAR and αV...
Main Author: | Thoma, CMM |
---|---|
Other Authors: | Morrison, J |
Format: | Thesis |
Language: | English |
Published: |
2011
|
Subjects: |
Similar Items
-
Combining regulatory angiogenic gene therapy and virotherapy for the treatment of breast cancer
by: Bazan Peregrino, M
Published: (2007) -
MRI and histological analysis of brain metastasis and the effect of systemic inflammation
by: Hamilton, AMA
Published: (2013) -
The role of ATF4 in hypoxia-induced cell death in cancer
by: Pike, L, et al.
Published: (2011) -
Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis
by: Winters, Z, et al.
Published: (2003) -
Exploiting pre-existing viral immunity for B cell vaccination against endogenous antigens
by: Wong, S
Published: (2013)